RAB9A

Chr X

RAB9A, member RAS oncogene family

Also known as: RAB9

Enables G protein activity; GDP binding activity; and GTP binding activity. Involved in positive regulation of exocytosis; receptor-mediated endocytosis; and regulation of protein localization. Located in late endosome; lysosome; and phagocytic vesicle. [provided by Alliance of Genome Resources, Jul 2025]

OMIMResearchGenerating clinical summary…

Clinical highlights

Interpreting a novel variant
This gene is strongly intolerant of loss-of-function variation in the population, so LoF variants warrant close attention. No curated mechanism annotation is available — see the mechanism card for the computational prediction and its caveats.Based on population constraint only.
0
Active trials
11
Pubs (1 yr)
—
P/LP submissions
—
P/LP missense
0.51
LOEUF
GOF
Mechanism· predicted

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?
0.51LOEUF
pLI 0.832
Z-score 2.25
OE 0.00 (0.00–0.51)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
1.28Z-score
OE missense 0.59 (0.46–0.76)
45 obs / 76.4 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.00 (0.00–0.51)
0≤0.351.4
Missense OE?0.59 (0.46–0.76)
0≤0.61.4
Synonymous OE?0.78
0≤1.21.6
LoF obs/exp: 0 / 5.9Missense obs/exp: 45 / 76.4Syn Z: 0.96

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

RAB9A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →